{"id":"https://openalex.org/W2087160901","doi":"https://doi.org/10.1097/cmr.0000000000000062","title":"Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-\u03b1 in patients with metastatic melanoma","display_name":"Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-\u03b1 in patients with metastatic melanoma","publication_year":2014,"publication_date":"2014-04-17","ids":{"openalex":"https://openalex.org/W2087160901","doi":"https://doi.org/10.1097/cmr.0000000000000062","mag":"2087160901","pmid":"https://pubmed.ncbi.nlm.nih.gov/24743052","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/4278368"},"language":"en","primary_location":{"id":"doi:10.1097/cmr.0000000000000062","doi":"https://doi.org/10.1097/cmr.0000000000000062","is_oa":false,"landing_page_url":"https://doi.org/10.1097/cmr.0000000000000062","pdf_url":null,"source":{"id":"https://openalex.org/S3207524","display_name":"Melanoma Research","issn_l":"0960-8931","issn":["0960-8931","1473-5636"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Melanoma Research","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4278368","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5061848220","display_name":"Anas Alrwas","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]},{"id":"https://openalex.org/I49332381","display_name":"University of Oklahoma Health Sciences Center","ror":"https://ror.org/0457zbj98","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I49332381"]},{"id":"https://openalex.org/I8692664","display_name":"University of Oklahoma","ror":"https://ror.org/02aqsxs83","country_code":"US","type":"education","lineage":["https://openalex.org/I8692664"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anas Alrwas","raw_affiliation_strings":["aHealth Science Center, University of Oklahoma, Oklahoma City, Oklahoma Departments of bMelanoma Medical Oncology cPalliative Care and Rehabilitative Medicine dBiostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA","Health Science Center, University of Oklahoma, Oklahoma City, Oklahoma"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"aHealth Science Center, University of Oklahoma, Oklahoma City, Oklahoma Departments of bMelanoma Medical Oncology cPalliative Care and Rehabilitative Medicine dBiostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA","institution_ids":["https://openalex.org/I1343551460","https://openalex.org/I8692664"]},{"raw_affiliation_string":"Health Science Center, University of Oklahoma, Oklahoma City, Oklahoma","institution_ids":["https://openalex.org/I49332381","https://openalex.org/I8692664"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103439037","display_name":"Nicholas E. Papadopoulos","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Nicholas E. Papadopoulos","raw_affiliation_strings":["Melanoma Medical Oncology","to Nicholas E. Papadopoulos, MD, Department of Melanoma Medical Oncology, Unit 430, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA Tel: +1 713 792 2921; fax: +1 713 745 1046; e-mail: [email\u00a0protected]","e-mail: [email\u00a0protected]","fax: +1 713 745 1046","to Nicholas E. Papadopoulos, MD, Department of Melanoma Medical Oncology, Unit 430, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA Tel: +1 713 792 2921"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Melanoma Medical Oncology","institution_ids":[]},{"raw_affiliation_string":"to Nicholas E. Papadopoulos, MD, Department of Melanoma Medical Oncology, Unit 430, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA Tel: +1 713 792 2921; fax: +1 713 745 1046; e-mail: [email\u00a0protected]","institution_ids":["https://openalex.org/I1343551460"]},{"raw_affiliation_string":"e-mail: [email\u00a0protected]","institution_ids":[]},{"raw_affiliation_string":"fax: +1 713 745 1046","institution_ids":[]},{"raw_affiliation_string":"to Nicholas E. Papadopoulos, MD, Department of Melanoma Medical Oncology, Unit 430, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA Tel: +1 713 792 2921","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072276912","display_name":"Suzanne Cain","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Suzanne Cain","raw_affiliation_strings":["Melanoma Medical Oncology"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Melanoma Medical Oncology","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035218748","display_name":"Sapna Pradyuman Patel","orcid":"https://orcid.org/0000-0003-1339-1517","observed_orcids":["https://orcid.org/0000-0003-1339-1517"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sapna P. Patel","raw_affiliation_strings":["Melanoma Medical Oncology"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Melanoma Medical Oncology","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015498468","display_name":"Kevin B. Kim","orcid":"https://orcid.org/0000-0003-0694-0530","observed_orcids":["https://orcid.org/0000-0003-0694-0530"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kevin B. Kim","raw_affiliation_strings":["Melanoma Medical Oncology"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Melanoma Medical Oncology","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052847871","display_name":"Tawania L Deburr","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Tawania L. Deburr","raw_affiliation_strings":["Palliative Care and Rehabilitative Medicine"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Palliative Care and Rehabilitative Medicine","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027845051","display_name":"Roland L. Bassett","orcid":"https://orcid.org/0000-0002-4534-2042","observed_orcids":["https://orcid.org/0000-0002-4534-2042"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Roland Bassett","raw_affiliation_strings":["Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5104110089","display_name":"Wen\u2010Jen Hwu","orcid":"https://orcid.org/0000-0003-1674-0751","observed_orcids":["https://orcid.org/0000-0003-1674-0751"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Wen-Jen Hwu","raw_affiliation_strings":["Melanoma Medical Oncology"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Melanoma Medical Oncology","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060563693","display_name":"Agop Y. Bedikian","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Agop Y. Bedikian","raw_affiliation_strings":["Melanoma Medical Oncology"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Melanoma Medical Oncology","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048327749","display_name":"Michael A. Davies","orcid":"https://orcid.org/0000-0002-0977-0912","observed_orcids":["https://orcid.org/0000-0002-0977-0912"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Michael A. Davies","raw_affiliation_strings":["Melanoma Medical Oncology"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Melanoma Medical Oncology","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006246174","display_name":"Scott Eric Woodman","orcid":"https://orcid.org/0000-0002-1157-6991","observed_orcids":["https://orcid.org/0000-0002-1157-6991"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Scott E. Woodman","raw_affiliation_strings":["Melanoma Medical Oncology"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Melanoma Medical Oncology","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5033798832","display_name":"Patrick Hwu","orcid":"https://orcid.org/0000-0002-8293-1313","observed_orcids":["https://orcid.org/0000-0002-8293-1313","https://orcid.org/0000-0003-0554-2856"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Patrick Hwu","raw_affiliation_strings":["Melanoma Medical Oncology"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Melanoma Medical Oncology","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5103439037"],"corresponding_institution_ids":["https://openalex.org/I1343551460"],"apc_list":null,"apc_paid":null,"fwci":1.1641,"has_fulltext":false,"cited_by_count":15,"citation_normalized_percentile":{"value":0.78908735,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":97},"biblio":{"volume":"24","issue":"4","first_page":"342","last_page":"348"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.9854000210762024,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.9854000210762024,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.0044999998062849045,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.0024999999441206455,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/metastatic-melanoma","display_name":"metastatic melanoma","score":0.9869999885559082},{"id":"https://openalex.org/keywords/biochemotherapy","display_name":"biochemotherapy","score":0.9359999895095825},{"id":"https://openalex.org/keywords/nab-paclitaxel","display_name":"nab-paclitaxel","score":0.9539999961853027},{"id":"https://openalex.org/keywords/cisplatin","display_name":"cisplatin","score":0.9860000014305115},{"id":"https://openalex.org/keywords/temozolomide","display_name":"temozolomide","score":1.0},{"id":"https://openalex.org/keywords/interleukin-2","display_name":"interleukin-2","score":0.968999981880188},{"id":"https://openalex.org/keywords/interferon-alpha","display_name":"interferon-alpha","score":0.9760000109672546},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.7720000147819519},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.9779999852180481},{"id":"https://openalex.org/keywords/central-nervous-system-metastases","display_name":"central nervous system metastasis","score":0.8970000147819519},{"id":"https://openalex.org/keywords/antitumor-immunity","display_name":"antitumor immunity","score":0.47699999809265137}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8822234272956848},{"id":"https://openalex.org/C2777389519","wikidata":"https://www.wikidata.org/wiki/Q425088","display_name":"Temozolomide","level":3,"score":0.6815725564956665},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.6560008525848389},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.6173015236854553},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.6111122965812683},{"id":"https://openalex.org/C2780964509","wikidata":"https://www.wikidata.org/wiki/Q416975","display_name":"Dacarbazine","level":3,"score":0.5804576873779297},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.5128019452095032},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5126606822013855},{"id":"https://openalex.org/C2777292972","wikidata":"https://www.wikidata.org/wiki/Q423762","display_name":"Paclitaxel","level":3,"score":0.508974552154541},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.4509333372116089},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.44704723358154297},{"id":"https://openalex.org/C2778496288","wikidata":"https://www.wikidata.org/wiki/Q6931269","display_name":"Mucositis","level":3,"score":0.4329320192337036},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.40058034658432007},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3730350136756897},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.35783112049102783}],"mesh":[{"descriptor_ui":"D000077204","descriptor_name":"Temozolomide","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D002945","descriptor_name":"Cisplatin","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D003606","descriptor_name":"Dacarbazine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D003606","descriptor_name":"Dacarbazine","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007376","descriptor_name":"Interleukin-2","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012878","descriptor_name":"Skin Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D012878","descriptor_name":"Skin Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D015331","descriptor_name":"Cohort Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016898","descriptor_name":"Interferon-alpha","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1097/cmr.0000000000000062","doi":"https://doi.org/10.1097/cmr.0000000000000062","is_oa":false,"landing_page_url":"https://doi.org/10.1097/cmr.0000000000000062","pdf_url":null,"source":{"id":"https://openalex.org/S3207524","display_name":"Melanoma Research","issn_l":"0960-8931","issn":["0960-8931","1473-5636"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Melanoma Research","raw_type":"journal-article"},{"id":"pmid:24743052","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/24743052","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Melanoma research","raw_type":"Clinical Trial, Phase I"},{"id":"pmh:oai:europepmc.org:3243118","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4278368","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":null,"raw_type":"Text"},{"id":"pmh:oai:pubmedcentral.nih.gov:4278368","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4278368","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"Melanoma Res","raw_type":"Text"}],"best_oa_location":{"id":"pmh:oai:europepmc.org:3243118","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4278368","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":null,"raw_type":"Text"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[{"id":"https://openalex.org/G1620252213","display_name":"Center for Clinical and Translational Sciences (CCTS)","funder_award_id":"UL1TR000371","funder_id":"https://openalex.org/F4320332161","funder_display_name":"National Institutes of Health"},{"id":"https://openalex.org/G3423162581","display_name":"Research Training in Academic Medical Oncology","funder_award_id":"T32CA009666","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G9000878657","display_name":"Cancer Center Support Grant","funder_award_id":"P30CA016672","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G9000879506","display_name":"Paul Calabresi Clinical Oncology Award","funder_award_id":"K12CA088084","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"}],"funders":[{"id":"https://openalex.org/F4320332161","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88"},{"id":"https://openalex.org/F4320332521","display_name":"University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07"},{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"},{"id":"https://openalex.org/F4320337472","display_name":"National Center for Advancing Translational Sciences","ror":"https://ror.org/04pw6fb54"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":5,"referenced_works":["https://openalex.org/W2008793220","https://openalex.org/W2017856888","https://openalex.org/W2043660086","https://openalex.org/W2067893090","https://openalex.org/W2113010159"],"related_works":["https://openalex.org/W2596571283","https://openalex.org/W1969738419","https://openalex.org/W2244771852","https://openalex.org/W2131788076","https://openalex.org/W2058026920","https://openalex.org/W2058667907","https://openalex.org/W2000912248","https://openalex.org/W2136271044","https://openalex.org/W2037221770","https://openalex.org/W1971140386"],"abstract_inverted_index":{"The":[0,103,127,170],"primary":[1],"objective":[2],"of":[3,16,22,45,153,197],"this":[4],"study":[5,217],"was":[6,85,91,106,113,131,176,184],"to":[7,28,173,207],"determine":[8,29],"the":[9,87,135,142,157,180,208,215],"safety,":[10],"toxicity,":[11],"and":[12,27,41,67,97,111,125,179,210],"maximum":[13,128],"tolerated":[14,129],"dose":[15,82,90,130,137,145],"nanoparticle":[17],"albumin-bound":[18],"(nab)-paclitaxel":[19],"as":[20],"part":[21],"biochemotherapy":[23],"for":[24,33,73,163],"metastatic":[25,235],"melanoma":[26],"whether":[30],"substituting":[31],"nab-paclitaxel":[32,88,136,205],"less":[34],"potent":[35],"agents":[36],"could":[37],"increase":[38],"response":[39],"rates":[40],"duration.":[42],"Treatment":[43],"consisted":[44],"intravenous":[46,69],"cisplatin":[47],"(20":[48],"mg/m)":[49,56,147],"on":[50,57,64,76,94,100,138],"days":[51,58,65,77],"1-4,":[52],"oral":[53],"temozolomide":[54,224],"(250":[55],"1-3,":[59],"subcutaneous":[60],"interferon-\u03b1":[61],"(5\u00d710":[62],"IU/m)":[63,72],"1-5,":[66],"continuous":[68],"interleukin-2":[70],"(9\u00d710":[71],"96":[74],"h":[75],"1-4.":[78],"A":[79],"standard":[80],"3+3":[81],"escalation":[83],"method":[84],"used;":[86],"starting":[89],"100":[92],"mg/m":[93,99],"day":[95,101,139],"1":[96,140],"70":[98],"5.":[102],"treatment":[104,201],"cycle":[105],"repeated":[107],"every":[108],"3":[109],"weeks":[110],"toxicity":[112,150],"assessed":[114],"weekly.":[115],"Ten":[116],"patients":[117,159,188,233],"were":[118,161],"enrolled.":[119],"Dose-limiting":[120],"toxicities":[121],"included":[122],"diarrhea,":[123],"transaminasemia,":[124],"neutropenia.":[126],"not":[132,226],"identified":[133],"because":[134],"at":[141,194],"lowest":[143],"planned":[144],"(80":[146],"caused":[148],"dose-limiting":[149],"in":[151,214,232],"two":[152],"five":[154,165],"patients.":[155],"Of":[156],"nine":[158],"who":[160],"evaluable":[162],"response,":[164],"had":[166],"a":[167,195],"partial":[168],"response.":[169],"median":[171,181,196],"time":[172],"disease":[174],"progression":[175],"5.30":[177],"months":[178,199],"overall":[182],"survival":[183],"8.73":[185],"months.":[186],"Six":[187],"developed":[189],"central":[190,228],"nervous":[191,229],"system":[192,230],"metastasis":[193,231],"5.33":[198],"after":[200],"initiation.":[202],"Biochemotherapy":[203],"including":[204],"according":[206],"doses":[209],"schedule":[211],"regimen":[212],"used":[213],"present":[216],"has":[218],"significant":[219],"toxicity.":[220],"Substituting":[221],"dacarbazine":[222],"with":[223,234],"did":[225],"prevent":[227],"melanoma.":[236]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":2},{"year":2019,"cited_by_count":2},{"year":2017,"cited_by_count":2},{"year":2016,"cited_by_count":1},{"year":2015,"cited_by_count":3},{"year":2014,"cited_by_count":1}],"updated_date":"2026-11-06T12:05:46.655746","created_date":"2016-06-24T00:00:00"}